Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02ZBW
|
|||
| Former ID |
DIB005411
|
|||
| Drug Name |
LC-150444
|
|||
| Synonyms |
LCD15-0444; Dipeptidyl peptidase IV inhibitors (oral, type 2 diabetes), LG Life Sciences
Click to Show/Hide
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 3 | [1] | |
| Company |
LG Life Sciences Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dipeptidyl peptidase 4 (DPP-4) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Protein digestion and absorption | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02089126) Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of ShangHai APIs Chemical. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.